Nykredit A/S’s Beam Therapeutics BEAM Stock Holding History

Nykredit A/S’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$74.7K	Buy	+2,178	New	+$65.8K	﹤0.01%	1406

Other funds holding BEAM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CGH

Contrarius Group Holdings Hamilton, Bermuda $2.17B AUM 134.87% 1-Year Est. Return

Nykredit A/S's BEAM Position: Q2 2026 in Review

Nykredit A/S opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 2,178 shares worth $74.7K. The stake represents ﹤0.01% of the portfolio and ranks #1406 among its holdings.

195 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Nykredit A/S held 2,178 shares of Beam Therapeutics worth $74.7K as of Q2 2026.
Beam Therapeutics was a new Nykredit A/S position in Q2 2026.
Beam Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1406 holding.
195 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.